From Diagnosis to Management: Navigating the Complex Terrain of Granulomatous Disease

Year 2024, Volume: 4 Issue: 2, 35 - 53, 29.04.2024

Hakan Koç Muhammet İlker Kaya Nizameddin Koca

https://doi.org/10.56016/dahudermj.1459557

Abstract

In the realm of granulomatous diseases, the convergence of pathophysiology, epidemiology, and therapeutic strategies presents a labyrinth of complexity with far-reaching clinical implications. This review embarks on a scholarly expedition through the intricate landscape of granulomatous inflammation, dissecting the multifaceted presentations ranging from infectious etiologies to enigmatic autoimmune disorders. With a discerning eye on recent advancements and literature, we unravel the nuanced interactions between host defenses and granuloma formation, alongside the pivotal role of cytokines and mononuclear cells in orchestrating these responses. Beyond a mere academic exercise, our exploration delves into the clinical juxtaposition of common and esoteric causes, offering a panoramic view on diagnostic methodologies that straddle the traditional and the innovative. The management of granulomatous diseases, often a tightrope walk balancing efficacy and toxicity, is critically examined, shedding light on conventional and emerging therapies that promise to reshape the therapeutic landscape. By weaving together threads of current research, this review aspires to enhance the understanding of granulomatous diseases and catalyze future inquiries into their mysteries. In doing so, it stands as a beacon for clinicians.

Keywords

Granulomatous Disease, granuloma, cytokines, mononuclear cell, tuberculosis, brucellosis, sarcoidosis, Q fever, Wegener

Ethical Statement

The local ethics committee approval (2011-KAEK-25 2019/07-01) was obtained, and the study was carried out in accordance with the declaration of Helsinki. A written informed consent was obtained from all participants.

Thanks

I would like to thank my estimable teacher Assoc. Prof. Dr. Nizameddin KOCA, who always supported his students in our Internal Medicine training, contributed to our progress and guided us, my colleague Dr. Muhammet İlker KAYA and my wife Lecturer Ayşe BAŞTUĞ KOÇ, who always supported me.

References

• James DG. A clinicopathological classification of granulomatous disorders. Postgrad Med J. 2000 Aug;76(898):457-65.
• Zumla A, James DG. Granulomatous Infections: Etiology and Classification, Clinical Infectious Diseases, Volume 23, Issue 1, July 1996, Pages 146–158,
• Flamm SL. Granulomatous liver disease. Clinics in liver disease. 2012;16.2: 387-396.
• Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases E-Book: 2-Volume Set. Elsevier health sciences, 2019.
• Sunnetcioglu A, Sunnetcioglu M, Binici I, Baran AI, Karahocagil MK, Saydan MR. Comparative analysis of pulmonary and extrapulmonary tuberculosis of 411 cases. Annals of clinical microbiology and antimicrobials, 2015;14, 34.
• Duguid JP. Expulsion of Pathogenic Organisms from Respiratory Tract. Br Med J. 1946 Feb 23;1(4442):265-8.
• Turkish Respiratory Research Association. Available at: https://solunum.org.tr/. Accessed March 25, 2024.
• Özçelik HU. Pediatric Face of Tuberculosis. Journal of Lung Health and İntensive care; 2021: pp. 25-35.
• Kocaman Karğı A. Detection of latent tuberculosis infection in hospital workers. 2010.
• Republic of Turkey Ministry of Health Tuberculosis Diagnosis and Treatment Guide; 2019: pp. 12.
• Raval AA, Goswami H, Parikh U, Shah P, Yadav KS. Extrapulmonary tuberculosis at tertiary health care center: a review. Journal of Infectious Diseases Letters, ISSN, 2013;0976-8904.
• Ceyhan İ, Şimşek H, Tarhan G. Comparison and evaluation of 2% Ogawa medium with Löwenstein-Jensen medium in the diagnosis of tuberculosis. 2012.
• Rieder HL, Chadha VK, Nagelkerke NJ, Van Leth F, Van Der Werf MJ. Guidelines for conducting tuberculin skin test surveys in high-prevalence countries. The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease. 2011 Jan;15 Suppl 1:S1-25.
• Iseman MD. Tuberculosis guide for clinicians. Translated by: Ozkara Ş. İstanbul Nobel Book Stores. 2002.
• Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis, 2017;64(2):111-115.
• Aslan R. The comparison of microscopy, culture and molecular methods for diagnosis of tubercolosis. 2015.
• Seymen FB. Examination of treatment side effects in pediatric tuberculosis cases followed between 2016-2021 at Uludağ University Department of Pediatric Infectious Diseases (Doctoral dissertation, Bursa Uludag University (Turkey)). 2022.
• Çimen P, Kayaalp İ, Ayrancı A, Güçlü SZ. A Case of lung Tuberculosis with atypical radiological findings. Izmir Chest Hospital Journal, 2014;28(3), 181-185.
• Okutan UDO. Lung Tuberculosis in adults. 2003.
• Uçar ZZ, Çakan A, Dereli Ş, Özsöz A, Soy Ö. Investigation of the frequency of parenchymal lesions in tuberculous pleurisy cases using high-resolution thorax computed tomography. 2002.
• Republic of Turkey Ministry of Health Communicable Diseases Notification and Reporting System Circular; 2015: pp. 18.
• Kalem E, Ağar E. Use of thioureas in the treatment of tuberculosis. Anadolu Bil Vocational School Journal, 2022; 16(64), 239-262.
• Özkara Ş, Arpaz S, Özkan S, Aktaş Z, Örsel O, Ecevit H. Directly observed therapy (DGT) in the treatment of tuberculosis. Respiratory Diseases. 2003;14(2), 150-7.
• Kuyucuoğlu Y. Brucella disease. Kocatepe Veterinary Journal, 2011;4(1), 57-64.
• Corbel MJ. Brucellosis in humans and animals. World Health Organization. 2006.
• Polat M, Kara SS, Tırhış Ö, Tapısız A, Tezer H. A Case of Fever of Unknown Origin with Brucellosis and the Prozone Phenomenon. Journal of Pediatric Disease, 2013;7(1,EK):29-31.
• Günal Ö, Bahadır-Ülger FE, Barut Ş, Ülger A. Osteoarticular Brucellosis. Klimik Journal, 2011;24(2).
• Sayılır K, Kutlu SS, Baykam N, Eren Ş, Çelikbaş AK, Dokuzoğuz B. Two human cases of brucellosis resulting in abortion. Journal of Infection, 2003;17(3), 345-348.
• Uluğ M, Can-Uluğ N. Evaluation of 78 Cases with Brucellosis. Klimik Journal, 2010;23(3).
• Dizer U, Beker CM, Çiçek H, Güner ÖR, Zeren İ, Pahsa A. Investigation of the effectiveness of brucellosis diagnostic methods. Uludağ University Faculty of Medicine Journal, 2005;31(2), 87-93.
• Evirgen Ö, Motor VK. Brucellosis. Journal of Experimental and Clinical Medicine, 2013;29(3s), 149–154.
• Yeni DK. Tularemia. Etlik Journal of Veterinary Microbiology, 2013;24(1), 20-25.
• Kılıç S, Yeşilyurt M. Tularemia: An Overview of Current Treatment Options. Klimik Journal, 2011;24(1)
• Korkmaz P, Naz H, Güçlüyener MN, Çağlan-Çevik F, Aykın N. Cat scratch disease: Case report. Klimik Journal, 2011;24(2), 116-8.
• Çelebi B. Bartonella henselae and infections. Microbiol Bull, 2008;42(1), 163-75.
• Bölük G, Mıstık R, Helvacı S, Yalçınkaya U, Nazlıoğlu HÖ. Three probable cat scratch disease cases treated with azithromycin. 2011.
• Ayvaz G, Kaygusuz S. Current approaches in the diagnosis and treatment of sexually transmitted diseases. Kırıkkale University Faculty of Medicine Journal, 2021;23(1), 143-156.
• Öztoklu İ, Yücel A. Chlamydia trachomatis infections. Ankara Medical Journal, 2012; 12(1), 32-36.
• Günal Ö, Barut Ş. Q Fever. Gaziosmanpaşa University Faculty of Medicine Journal, 2011;3(3), 28–29.
• Bucuk PS, Sırmatel FA. Forgotten Zoonotic Disease: Q Fever. Abant Medical Journal, 2022;11(1), 132-142.
• Saltoğlu N. Invasive Mycoses: Clinical Appearances. Flora Journal of Infectious Diseases and Clinical Microbiology, 2006;11(4), 169-180.
• Bezmialem Vakif University Department of Infectious Diseases and Clinical Microbiology. Turkish Infectious Diseases and Clinical Microbiology Specialization Association. HIV-related fungal infections. Available at: https://www.ekmud.org.tr/. Accessed March 25, 2024.
• Hunnınghake GW. Statement on sarcoidosis. Am J Respir Crit. Care Med, 1999;160, 736-755.
• Çetinoğlu ED. Epidemiology of Interstitial Lung Disease in Turkey and the World. Current Chest Diseases Series, 2014;2(3), 257-262.
• Musellim B, Kumbasar OO, Ongen G, et al. Epidemiological features of Turkish patients with sarcoidosis. Respir Med. 2009;103(6):907-912.
• Yönetimine LH, Zengin F. Contribution of lymphocyte-dominant bronchoalveolar lavage to disease management and treatment in interstitial lung diseases. 2020.
• Kutbay Özçelik H, Bayram M, Büyükbaşılı NP, et al. Sarcoidosis with Pleural Involvement. 2014.
• Hamzeh N. Sarcoidosis. The Medical clinics of North America, 2011,95(6), 1223–1234.
• Judson MA. The Symptoms of Pulmonary Sarcoidosis. Journal of clinical medicine, 2023;12(18), 6088.
• Keir G, Wells AU. Assessing pulmonary disease and response to therapy: which test?. In Seminars in respiratory and critical care medicine, (2010, August; Vol. 31, No. 04, pp. 409-418). © Thieme Medical Publishers.
• Abakay Ö. Innovations in Sarcoidosis Diagnosis and Treatment. Current Chest Disease Series, 2014; 2(3), 379-86.
• Salazar A, Mana J, Corbella X, Albareda JM, Pujol R. Splenomegaly in sarcoidosis: a report of 16 cases. Sarcoidosis, 1995;12(2), 131-134.
• Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis, vasculitis, and diffuse lung diseases: official journal of WASOG, 2012;29(2), 119-127.
• Tatoğlu MS, Gülbaran Z. Frequency of pulmonary hypertension in sarcoidosis patients. 2020.
• Ungprasert P, Tooley AA, Crowson CS, Matteson EL, Smith WM. Clinical characteristics of ocular sarcoidosis: a population-based study 1976–2013. Ocular immunology and inflammation, 2019;27(3), 389-395.
• Cozier YC, Berman JS, Palmer JR, Boggs DA, Serlin DM, Rosenberg L. Sarcoidosis in black women in the United States: data from the Black Women’s Health Study. Chest, 2011;139(1), 144-150.
• Lynch III JP, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clinics in Chest Medicine, 1997;18(4), 755-785.
• Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. European Respiratory Journal, 2008;31(2):372-379.
• Deutsch-Link S, Fortuna D, Weinberg EM. A comprehensive review of hepatic sarcoid. In Seminars in Liver Disease, (2018, August,Vol. 38, No. 03, pp. 284-297). Thieme Medical Publishers.
• Ungprasert P, Crowson CS, Simonetto DA, Matteson EL. Clinical characteristics and outcome of hepatic sarcoidosis: a population-based study 1976–2013. Official journal of the American College of Gastroenterology ACG, 2017;112(10), 1556-1563.
• Ungprasert P, Matteson EL. Neurosarcoidosis. Rheumatic Disease Clinics, 2017;43(4), 593-606.
• Berliner AR, Haas M, Choi MJ. Sarcoidosis: the nephrologist’s perspective. American Journal of Kidney Diseases, 2006;48(5), 856-870.
• Loncope WT. A study of sarcoidosis: Based on a combined investigation of 160 cases, including 30 autopsies from the Johns Hopkins Hospital and Massachusetts General Hospital. Medicine, 1952;31, 1-132.
• Hamzeh N, Steckman DA, Sauer WH, Judson MA. Pathophysiology and clinical management of cardiac sarcoidosis. Nature Reviews Cardiology, 2015;12(5), 278-288.
• Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation, 2015; 131(7), 624-632.
• Chapelon-Abric C, de Zuttere D, Duhaut P, Veyssier P, Wechsler B, de Gennes C, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine, 2004;83(6), 315-334.
• Hu X, Carmona EM, Yi ES, Pellikka PA, Ryu J. Causes of death in patients with chronic sarcoidosis. Sarcoidosis, vasculitis, and diffuse lung diseases: official journal of WASOG, 2016;33(3), 275-280.
• Yserbyt J, Wells AU. Sarcoidosis: pulmonary manifestations and management. Pulmonary Manifestations of Systemic Diseases; European Respiratory Society (ERS): Lausanne Switzerland, 2019;404-418.
• In Özlü T, Metintaş M, Karadağ M, Kaya A, eds. Respiratory System and Diseases Basic Reference Book. Istanbul. Istanbul Medical Bookstore; 2010: pp. 813-817.
• Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet (London, England), 2014;383(9923), 1155–1167.
• Wessendorf TE, Bonella F, Costabel U. Diagnosis of sarcoidosis. Clinical reviews in allergy & immunology, 2015;49, 54-62.
• Costabel U, Bonella F, Ohshimo S, Guzman J. Diagnostic modalities in sarcoidosis: BAL, EBUS, and PET. In Seminars in respiratory and critical care medicine, (2010, August;Vol. 31, No. 04, pp. 404-408). © Thieme Medical Publishers.
• Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax, 1996;51(3), 238-247.
• Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999 Aug;160(2):736-55.
• Paramothayan S, Lasserson T. Treatments for pulmonary sarcoidosis. Respiratory medicine, 2008;102(1), 1-9.
• Ungprasert P, Ryu JH, Matteson EL. Clinical manifestations, diagnosis, and treatment of sarcoidosis. Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2019;3(3), 358-375.
• Hartavi M. Investigation of Cytokine Signal Suppressor (SOCS)-1 1478 CA/DEL Gene Polymorphism in Patients Diagnosed with Ulcerative Colitis (Doctoral dissertation, Bursa Uludag University (Turkey)). 2012.
• Peppercorn MA, Kane SV. Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults. UpToDate (Accessed on December 2014). 2020.
• Ozin Y, Kilic MZ, Nadir I, Cakal B, Disibeyaz, S, Arhan M, et al. Clinical features of ulcerative colitis and Crohn’s disease in Turkey. J Gastrointestin Liver Dis, 2009;18(2), 157-62.
• Köseler E. Nutrition in ulcerative colitis. Current Gastroenterology, 2016;20(3), 263-266.
• Broekroelofs J, Mulder AHL, Nelis GF, Westerveld BD, Cohen Tervaert JW, et al. Antineutrophil cytoplasmic antibodies (ANCA) in sera from patients with inflammatory bowel disease (IBD) Relation to disease pattern and disease activity. Digestive diseases and sciences, 1994;39, 545-549.
• Hasanova G, Barutçuoğlu B, Üna NG, Ak G, Özütemiz Ö. Early Prediction of Disease Activity in Crohn’s Patients in Clinical Remission. 2019.
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis. British medical journal, 1955;2(4947), 1041.
• Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial. Gut, 2011;60(6), 780–787.
• Sandborn WJ. Pouchitis following heal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology, 1994;107(6), 1856-1860.
• Mercimek K. Epidemiological characteristics of inflammatory bowel diseases in the Thrace region. 2010.
• Göksel S. Pathological Features of Crohn’s Disease. Cerrahpaşa Medical Journal, 2009;40(3), 103-120.
• Smale S, Natt RS, Orchard TR, Russell AS, Bjarnason I. Inflammatory bowel disease and spondylarthropathy. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 2001;44(12), 2728-2736.
• Kul S. The role of small intestine bacterial overgrowth in inflammatory bowel diseases. 2018.
• Scotiniotis I, Rubesin SE, Ginsberg GG. Imaging modalities in inflammatory bowel disease. Gastroenterology Clinics of North America, 1999;28(2), 391-421.
• Şenkal İV. The effect of mesenchymal stromal cells on inflammatory and pro-inflammatory cytokines in the Crohn’s disease model and their use in treatment. 2010.
• Şahin B. Retrospective analysis of antiTNF therapy in inflammatory bowel diseases (Doctoral dissertation, Bursa Uludag University (Turkey)). 2018.
• Doecke JD, Hartnell F, Bampton P, Bell S, Mahy G, Grover Z. et al. Infliximab vs. adalimumab in Crohn’s disease: results from 327 patients in an Australian and New Zealand observational cohort study. Alimentary Pharmacology & Therapeutics, 2017;45(4), 542-552.
• De Medeiros CR, Setúbal DC. Autoimmune hemolytic anemia as a complication of primary biliary cirrhosis. 2004.
• Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (Eds.), Harrison’s Principles of Internal Medicine; 2017: pp. 1974.
• Sezer BT, Sezer, Ö, Oygen Ş, Çalışkan CK, Borlu F. Primary sclerosing cholangitis without icterus in a seventeen-year-old male patient-case report. 2011.
• Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology, 1999;30(1), 325-332.
• Tekin F, Görümlü G, Yüce G, Soydan S, et al. Coexistence of multiple myeloma and primary biliary cirrhosis: A case report. Academic Journal of Gastroenterology, 2008;7(2).
• Sherlock S. Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis. Clinics in Liver Disease, 2000;4(1), 97-113.
• Suzuki N. Kansas G Engleman EG: Lymphocytes. Arthritis and alhed conditions. McCarty DJ, Koopman WJ (Eds). Lea and Febiger, 1993;pp, 377–387.
• Bozkurt A, Gök M. Effects of steroid and methotrexate treatment on cardiac functions in patients with rheumatoid arthritis. 2016.
• Boz M, Ülgen E, Ergüney M, Ünalan N, Pişkinpaşa E. Extra-articular symptoms in rheumatoid arthritis. Istanbul Medical Journal, 2006;1, 26-31.
• Göksoy T. Diagnosis and treatment of rheumatic diseases. Yüce Advertising Publishing Distribution. 2002.
• Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (Eds.), Harrison’s Principles of Internal Medicine; 2017: pp. 2087.
• Sertpoyraz FM, Köse Ş, Öztürk Y. The relationship between rheumatoid factor and anti-CCP in patients with rheumatoid arthritis. Tepecik Training Hospital Journal, 2013;23(2), 93-6.
• Demirel A, Kırnap M. Traditional and current approaches in rheumatoid arthritis treatment. Journal of Health Sciences, 2010;19(1), 74-84.
• Şahin S, Balcan B, Kızıltaş Ş, Aydın M. A Case of Wegener’s Granulomatosis Complicated with Brain Abscess Due to Nocardia. Journal of Academic Research in Medicine, 2016;6(2).
• Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Annals of Internal Medicine, 1992;116(6), 488-498.
• Vignes S, Chaillet M, Cabane J, Piette JC. Perforation de la cloison nasale et maladies systémiques. La Revue de médecine interne, 2002;23(11), 919-926.
• Ergün P, Biber Ç, Erdoğan Y, et al. Wegener’s granulomatosis: evaluation of eight cases. Journal of Tuberculosis and Thorax, 2001;49(3), 477-82.
• Leavitt RY, Fauci AS. Less common manifestations and presentations of Wegener’s granulomatosis. Current opinion in rheumatology, 1992;4(1), 16-22.
• Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis: a literature review and meta-analysis. Annals of Internal Medicine, 1995;123(12), 925-932.
• Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg–Strauss syndrome). Journal of autoimmunity, 2014;48, 99-103.
• Çelik Y, Kızıltan G, Yaldıran A, Büge ÖZ. Development of mononeuritis multiplex in a case with bronchial asthma: Churg-Strauss syndrome. Cerrahpaşa Medical Journal, 2014;31(2).
• Rahman W, Rahman FZ. Giant cell (temporal) arteritis: an overview and update. Survey of ophthalmology, 2005;50(5), 415-428.
• Coşkun Ö, Gül HC, Savaşçı Ü, Durmaz A, Eyigün CP. A case of fever with an unknown reason, diagnosed with temporal arteritis, with positional vertigo. Gazi Medical Journal, 2009;20(1).
• Kiki İ, Gündoğdu M, Erdem F, Sarı RA. A Case of Temporal Arteritis with Atypical Clinical Presentation. Journal of Turgut Ozal Medical Center, 2007;14(3), 207-210.
• Şenay EH. HLA genotyping in cardiac and noncardiac involvement of sarcoidosis patients. 2020.
• Fireman E, Haimsky E, Noiderfer M, Priel I, Lerman Y. Misdiagnosis of sarcoidosis in patients with chronic beryllium disease. Sarcoidosis, vasculitis, and diffuse lung diseases: official journal of WASOG, 2003;20(2), 144-148.
• Handa T, Nagai S, Kitaichi M, Chin K, Ito Y, Oga T, et al. Long-term complications and prognosis of chronic beryllium. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2009;26, 24-31.
• Küpeli E, Karnak D. Hypersensitivity pneumonitis. Tuberculosis and Thorax Journal, 2011;59(2), 194-204.
• Costabel U, Guman J. Less common diseases: hypersensitivity pneumonitis. Diffuse Lung Disease. A Practical Approach. London: Arnold, 2004;203-12.
• Lacasse Y, Selman M, Costabel U, Dalphin JC, Ando M, Morell F, et al. Clinical diagnosis of hypersensitivity pneumonitis. American journal of respiratory and critical care medicine, 2003;168(8), 952-958.